NK Cell Therapy in Osaka: What International Patients Should Know

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

If you or a family member is living with cancer, you may have come across NK cell therapy while searching for options beyond surgery, chemotherapy, or radiation. This article explains, in plain terms, what international patients and residents in Japan should understand before booking a consultation at Grand Green Osaka Umekita Clinic in Osaka. It is general information, not medical advice.

The short answer: it is a possible add-on, not a replacement

NK cell therapy is an immune cell therapy that uses your own natural killer (NK) cells. It is offered in Japan as a self-pay (non-insured) treatment, and it is not intended to replace standard cancer treatment. Whether it makes sense for you depends on your diagnosis, your current treatment plan, and your overall health, and that can only be judged by a physician after an in-person or remote consultation. No treatment can promise a particular outcome, and this therapy is no exception.

What are NK cells, and what is the idea behind the therapy?

NK cells are a type of lymphocyte that circulates in the blood. They are part of the innate immune system and can recognize and attack abnormal cells, such as some cancer cells and virus-infected cells, without waiting for instructions from other immune cells. This is often described as immune surveillance.

Research suggests that NK cell activity can decline with age, chronic stress, and the effects of cancer itself. In NK cell therapy, NK cells are obtained from a routine blood draw, activated and expanded at a specialized cell processing facility, and then returned to your body by intravenous infusion. The aim is to supplement immune function with a larger number of more active cells. Studies of NK cell approaches are ongoing, and results vary by cancer type and study design, so a single study should not be read as proof that the therapy will work for any individual.

How it can fit alongside standard cancer treatment

Many patients ask whether they must choose between standard treatment and immune cell therapy. In general, NK cell therapy is considered as a complement. Because the treatment involves a blood draw and an infusion rather than surgery, it is typically discussed as something that can be scheduled around other treatments. Your oncologist remains the key decision-maker for your core cancer care.

If you are currently being treated elsewhere, it helps to bring a clear picture of your situation to the consultation:

• Your diagnosis, stage, and the date of diagnosis, if known
• A summary of treatments received so far and any currently planned
• Recent blood test and imaging reports, ideally with English or Japanese documentation
• A list of your current medications and any known allergies

With your permission, the clinic can coordinate with the medical institution providing your standard treatment, so that everyone involved understands the plan.

What the process generally looks like

Although details are confirmed by your physician, the general flow is simple. After an initial consultation, a blood sample is collected. The NK cells are then cultured and expanded over a period of time at a cell processing facility. Once ready, the cells are returned through an intravenous drip, usually without hospitalization. Because the therapy uses your own cells, the risk of rejection is considered low, but temporary reactions such as fever or fatigue may occur. As with any medical treatment, other risks cannot be ruled out, which is why a careful medical interview comes first.

In Japan, cell-based treatments of this kind are provided under the Act on the Safety of Regenerative Medicine, which requires a treatment plan to be submitted to and accepted by the authorities and requires the use of licensed cell processing facilities. This framework is about safety management and procedure. It does not mean that effectiveness is guaranteed.

Questions to ask before you decide

A good consultation should leave you with clear answers. Consider asking the following:

• Is NK cell therapy suitable for my type and stage of cancer, and why or why not?
• What are the known risks, side effects, and limitations in my situation?
• How many infusions are proposed, over what period, and what is the total cost, including any additional charges?
• How will my response be monitored, and when would we reconsider the plan?
• How will you communicate with my oncologist, and can documents be shared in English?

Because this is a self-pay treatment, fees are not covered by Japan’s national health insurance and may not be covered by overseas insurance either. Please confirm pricing, number of sessions, and treatment period directly on the clinic’s fees page or during consultation rather than relying on estimates found elsewhere.

Consulting in Osaka as an international patient

Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka, which is easy to reach from Kansai International Airport and Shin-Osaka Station. The clinic provides an information page for foreign patients, and you can start by reading the NK Cell Therapy page and the fees and flow sections to prepare your questions. If you are traveling for treatment, think about the practical side too: how long you can stay, whether follow-up can be arranged in your home country, and how your records will be transferred.

The most important step is to talk with a physician about your own circumstances. Bring your medical records, write down your questions in advance, and take your time. NK cell therapy may be one option worth understanding, but the decision should always be made together with your doctors, with standard treatment kept at the center of your care.

1. 1Talk with a physicianJudged case by case
2. 2Bring your recordsDiagnosis and treatment history
3. 3Ask your questionsRisks, sessions, and fees
4. 4Self-pay treatmentNot covered by national insurance
5. 5Japanese legal framework

This figure is a conceptual diagram summarizing the article

References

• PubMed: CAR-NK cell therapy: promise and challenges in solid tumors. (2025)
• PubMed: Natural killer cell therapies. (2024)
• PubMed: Natural killer cell-based immunotherapy for cancer. (2025)
• PubMed: Allogeneic natural killer cell therapy. (2023)
• PubMed: NK cells and ILCs in tumor immunotherapy. (2021)
• PMC: Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. (2011)
• PMC: Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. (2019)
• PMC: Natural killer cell-based immunotherapy for cancer. (2025)
• MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.